Vol. 6 No. 1 (2019): January-December 2019

DOI: https://doi.org/10.1177/2284240319877892
Published: 2019-12-31

Review

  • Cost per response/remission in biologics available in Italy for the treatment of TNF-α inhibitors-naïve patients with ulcerative colitis

    Matteo Ruggeri, Francesca Romana Rolli
    DOI: https://doi.org/10.33393/grhta.2019.456

  • SIR-Spheres® Y-90 resin microspheres in chemotherapy refractory or intolerant patients with metastatic colorectal cancer

    Silvia Coretti, Filippo Rumi, Dario Sacchini, Americo Cicchetti
    DOI: https://doi.org/10.33393/grhta.2019.458

  • The offset effect of pharmaceutical innovation: A review study

    Néboa Zozaya, Bleric Alcalá, Jhon Galindo
    DOI: https://doi.org/10.33393/grhta.2019.454

  • A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus

    Néboa Zozaya, Margarita Capel, Susana Simón, Alfonso Soto-González
    DOI: https://doi.org/10.33393/grhta.2019.453

Point of View

  • Early Access in Oncology: Why Is It Needed?

    Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Mario Alberto Clerico, Pierfranco Conte, Filippo de Braud, Francesco De Lorenzo, Maria Gabriella Ferrandina, Armando Genazzani, Stefania Gori, Michele Maio, Mauro Patroncini, Francesco Perrone, Giovanni Scambia, Giovanna Scroccaro
    DOI: https://doi.org/10.33393/grhta.2019.461

Original Research Articles

  • Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy

    Roberto Ravasio, Silvia Antonelli, Alessia Maiorino, Antonio Costanzo, Serena Losi
    DOI: https://doi.org/10.33393/grhta.2019.468

  • Analysis of the budgetary impact of alemtuzumab as second-line therapy, compared to natalizumab and fingolimod, in patients previously treated with interferon beta 1b, diagnosed with active relapsing-remitting multiple sclerosis, treated in the Costa Rican social security fund

    Luis Pastor Quirós, Rocío Ugalde
    DOI: https://doi.org/10.33393/grhta.2019.467

  • Twenty Years of Hepatitis C in the Treviso District (Local Health Unit 2): Treatments, Clinical Management and Cost Analysis

    Annachiara Bellin, Giulia Franchin, Jenny Bolcato, Alessandra Bettiol, Roberta Pirolo, Alberto Schiavon, Pietro Giusti, Michele Tessarin, Alessandro Chinellato
    DOI: https://doi.org/10.33393/grhta.2019.466

  • The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy

    Sanja Stanisic, Antonio Bertolotto, Patrizia Berto, Paolo Di Procolo, Julia Morawski
    DOI: https://doi.org/10.33393/grhta.2019.465

  • Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis

    Carlo Lazzaro, Nicola Amedeo Mazzanti, Fabio Parazzini
    DOI: https://doi.org/10.33393/grhta.2019.464

  • The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri® PharmacoEconomics (TyPE) Study

    B Polistena, F Spandonaro, R Capra, S Fantaccini, L Santoni, GB Zimatore, C Gasperini
    DOI: https://doi.org/10.33393/grhta.2019.463

  • Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

    R. Ravasio, M. Tiseo, L. Pradelli, M. Bellone, A. Gervasi, M. Coffani
    DOI: https://doi.org/10.33393/grhta.2019.462

  • The economic impact of biosimilars in Italy: a scenario analysis

    Francesco S Mennini, Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Alessandro Giunta, Antonio Gasbarrini, Guido Valesini, Pier Luigi Canonico, Ettore Novellino, Valentina Orlando, Alessandra Mecozzi, Teresa Gamucci, Livio Pagano, Eugenio Di Brino, Matteo Ruggeri, Americo Cicchetti
    DOI: https://doi.org/10.33393/grhta.2019.457

  • Monitoring treatment response in metastasic colorectal cancer: Economic evaluation of PrediCTC versus computed tomography scan

    Cristina Antón Rodríguez, Miguel Abal Posada, Lorena Alonso Alconada, Sonia Candamio Folgar, Rafael López López, Carlos Martín-Saborido
    DOI: https://doi.org/10.33393/grhta.2019.459

  • Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals

    Claudio Jommi, Marianna Cavazza
    DOI: https://doi.org/10.33393/grhta.2019.460

  • Cost of illness of spinal muscular atrophy (SMA) in Italy

    Andrea Marcellusi, Chiara Bini, Jacopo Casiraghi, Francesco D’Ambrosio, Maria A. Rotundo, Anita Pallara, Francesco S. Mennini
    DOI: https://doi.org/10.33393/grhta.2019.455

  • Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses

    Nicola Amedeo Mazzanti, Carolina Scauri, Bianca Domini, Chiara Vassallo, Simone Cusato, Chiara De Fino, Filippo de Marinis
    DOI: https://doi.org/10.33393/grhta.2019.451

  • Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

    Maria Teresa Álvarez-Román, Ignacio Cuervo-Arango, Rafael Pérez-Santamarina, José Luís Poveda, José Antonio Romero, Amparo Santamaría, José Luís Trillo-Mata, Marina Tort, Xavier Badia
    DOI: https://doi.org/10.33393/grhta.2019.452